News | March 13, 2025
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Subscribe To Our Newsletter & Stay Updated
